These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 16139581

  • 1. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.
    Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ.
    Biol Psychiatry; 2005 Sep 01; 58(5):355-63. PubMed ID: 16139581
    [Abstract] [Full Text] [Related]

  • 2. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression.
    George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R, Kling MA, Moreno F, Rittberg B, Dunner D, Schwartz T, Carpenter L, Burke M, Ninan P, Goodnick P.
    Biol Psychiatry; 2005 Sep 01; 58(5):364-73. PubMed ID: 16139582
    [Abstract] [Full Text] [Related]

  • 3. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.
    Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG.
    Biol Psychiatry; 2005 Sep 01; 58(5):347-54. PubMed ID: 16139580
    [Abstract] [Full Text] [Related]

  • 4. Vagus nerve stimulation for depression: efficacy and safety in a European study.
    Schlaepfer TE, Frick C, Zobel A, Maier W, Heuser I, Bajbouj M, O'Keane V, Corcoran C, Adolfsson R, Trimble M, Rau H, Hoff HJ, Padberg F, Müller-Siecheneder F, Audenaert K, Van den Abbeele D, Stanga Z, Hasdemir M.
    Psychol Med; 2008 May 01; 38(5):651-61. PubMed ID: 18177525
    [Abstract] [Full Text] [Related]

  • 5. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome.
    Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, Johnson CR, Seidman S, Giller C, Haines S, Simpson RK, Goodman RR.
    Neuropsychopharmacology; 2001 Nov 01; 25(5):713-28. PubMed ID: 11682255
    [Abstract] [Full Text] [Related]

  • 6. Two-year outcome of vagus nerve stimulation in treatment-resistant depression.
    Bajbouj M, Merkl A, Schlaepfer TE, Frick C, Zobel A, Maier W, O'Keane V, Corcoran C, Adolfsson R, Trimble M, Rau H, Hoff HJ, Padberg F, Müller-Siecheneder F, Audenaert K, van den Abbeele D, Matthews K, Christmas D, Eljamel S, Heuser I.
    J Clin Psychopharmacol; 2010 Jun 01; 30(3):273-81. PubMed ID: 20473062
    [Abstract] [Full Text] [Related]

  • 7. Concomitant use of vagus nerve stimulation and electroconvulsive therapy for treatment-resistant depression.
    Burke MJ, Husain MM.
    J ECT; 2006 Sep 01; 22(3):218-22. PubMed ID: 16957540
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after FDA approval: outcomes at 1 year.
    Cristancho P, Cristancho MA, Baltuch GH, Thase ME, O'Reardon JP.
    J Clin Psychiatry; 2011 Oct 01; 72(10):1376-82. PubMed ID: 21295002
    [Abstract] [Full Text] [Related]

  • 9. Clinical issues in considering vagus nerve stimulation for treatment-resistant depression.
    Rush AJ, Siefert SE.
    Exp Neurol; 2009 Sep 01; 219(1):36-43. PubMed ID: 19397908
    [Abstract] [Full Text] [Related]

  • 10. Introduction of vagus nerve stimulation into a maintenance electroconvulsive therapy regimen: a case study and cost analysis.
    Warnell RL, Elahi N.
    J ECT; 2007 Jun 01; 23(2):114-9. PubMed ID: 17548984
    [Abstract] [Full Text] [Related]

  • 11. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients.
    Feighner JP, Sverdlov L, Hlavka J, Nicolau G, Cartwright K, Freed JS.
    Int Clin Psychopharmacol; 2008 Jan 01; 23(1):29-35. PubMed ID: 18090505
    [Abstract] [Full Text] [Related]

  • 12. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients.
    Carpenter LL, Moreno FA, Kling MA, Anderson GM, Regenold WT, Labiner DM, Price LH.
    Biol Psychiatry; 2004 Sep 15; 56(6):418-26. PubMed ID: 15364040
    [Abstract] [Full Text] [Related]

  • 13. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.
    Zimmerman M, Posternak MA, Chelminski I.
    J Psychiatr Res; 2004 Sep 15; 38(6):577-82. PubMed ID: 15458853
    [Abstract] [Full Text] [Related]

  • 14. The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression.
    Sackeim HA, Keilp JG, Rush AJ, George MS, Marangell LB, Dormer JS, Burt T, Lisanby SH, Husain M, Cullum CM, Oliver N, Zboyan H.
    Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan 15; 14(1):53-62. PubMed ID: 11234909
    [Abstract] [Full Text] [Related]

  • 15. Vagus nerve stimulation in treatment-resistant depression: acute and follow-up results of an italian case series.
    Dell'Osso B, Oldani L, Palazzo MC, Balossi I, Ciabatti M, Altamura AC.
    J ECT; 2013 Mar 15; 29(1):41-4. PubMed ID: 23303420
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov 15; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 17. VNS and depression: current status and future directions.
    Walsh SP, Kling MA.
    Expert Rev Med Devices; 2004 Sep 15; 1(1):155-60. PubMed ID: 16293018
    [Abstract] [Full Text] [Related]

  • 18. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M.
    J Affect Disord; 2009 Jun 15; 115(3):439-49. PubMed ID: 19027961
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.
    Int Clin Psychopharmacol; 2007 Nov 15; 22(6):338-47. PubMed ID: 17917552
    [Abstract] [Full Text] [Related]

  • 20. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression.
    Dell'Osso B, Mundo E, D'Urso N, Pozzoli S, Buoli M, Ciabatti M, Rosanova M, Massimini M, Bellina V, Mariotti M, Altamura AC.
    Bipolar Disord; 2009 Feb 15; 11(1):76-81. PubMed ID: 19133969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.